Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MTOR | P42345 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | HBB | P68871 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CDA | P32320 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182161 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL41572 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL18512948 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL2579580 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL14441083 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL6297856 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL5953706 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL5697581 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL5953287 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB | |
| SCHEMBL15630246 | 1.00 | LMNA (0.62) | LMNAMTORALDH1A1TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170044619-A1 | PROFILING CHEMICALLY MODIFIED DNA/RNA UNITS FOR DISEASE AND CANCER DIAGNOSIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-02-16 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | LMNA 422/4885MTOR 4525/4885ALDH1A1 1969/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | LMNA 585/4885MTOR 4256/4885ALDH1A1 2620/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | LMNA 585/4885MTOR 4256/4885ALDH1A1 2620/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | LMNA 571/4885MTOR 4711/4885ALDH1A1 2324/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | LMNA 422/4885MTOR 4525/4885ALDH1A1 1969/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | LMNA 571/4885MTOR 4711/4885ALDH1A1 2324/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | LMNA 571/4885MTOR 4711/4885ALDH1A1 2324/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | LMNA 422/4885MTOR 4525/4885ALDH1A1 1969/4885 |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | TYMP, ADA, CDA | LMNA 1415/4885MTOR 3720/4885ALDH1A1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.